[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"resistance-to-immunotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:resistance-to-immunotherapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100617888","phase-2-ivarmacitinib-combined-with-camrelizumab-and-apatinib-for-unresectable-advanced-hepatocellular-carcinoma-with-acquired-resistance-to-immune-checkpoint-therapy-a-single-arm-exploratory-clinical-study-100617888",false,"NCT07324473","Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study","Inclusion Criteria:\n\n1. Patients with a diagnosis of hepatocellular carcinoma, confirmed either by clinical diagnosis (per the Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer \\[2022 Edition\\]) or by pathological diagnosis.\n2. Patients classified as Barcelona Clinic Liver Cancer (BCLC) stage B and assessed by the responsible hepatobiliary surgeon as unsuitable for radical resection, or patients with BCLC stage C disease.\n3. Patients with unresectable hepatocellular carcinoma who have developed secondary (acquired) drug resistance. This is defined as having received at least 4 cycles of a first-line targeted therapy combined with immunotherapy regimen recommended by guidelines . Eligible prior regimens include specified combinations (e.g., Camrelizumab + Apatinib; Atezolizumab + Bevacizumab; Sintilimab + Bevacizumab) or other guideline-recommended first-line targeted agents (Donafenib, Lenvatinib, Sorafenib, Cabozantinib, Regorafenib) combined with first-line immunotherapy (Tislelizumab, Durvalumab, Pembrolizumab). Furthermore, patients must have achieved a partial response in the primary lesion but subsequently experienced disease progression after the 4th immunotherapy cycle, as confirmed per RECIST 1.1 criteria (including increase in size of primary lesion, or emergence of new lesions\u002Fmetastases).\n4. At least one measurable lesion according to RECIST 1.1 criteria (target lesion with longest diameter ≥ 10 mm, or lymph node with short axis ≥ 15 mm).\n5. Anticipated life expectancy \\> 3 months.\n6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n7. Adequate organ and bone marrow function, as evidenced by the following laboratory values within 7 days prior ： (1)Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL in the absence of granulocyte colony-stimulating factor support within the last 14 days; (2)Platelets ≥ 60 × 10⁹\u002FL without transfusion within the last 14 days; (3)Hemoglobin \\> 9 g\u002FdL without transfusion or erythropoietin use within the last 14 days; (4)Total bilirubin ≤ 2 × upper limit of normal (ULN); (5)Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; (6)Serum creatinine ≤ 1.5 × ULN and creatinine clearance (calculated using the Cockcroft-Gault formula) ≥ 60 mL\u002Fmin; (7)Adequate coagulation function, defined as an International Normalized Ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN; (8)Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, study participants may still be enrolled if total T3 (or free T3) and free T4 are within the normal range; (9)Myocardial enzyme profile within normal limits (isolated laboratory abnormalities judged by the investigator as clinically insignificant are also permitted);\n8. For female study participants of childbearing potential, a negative urine or serum pregnancy test must be obtained within 3 days prior to the first dose of study drug (Cycle 1, Day 1). If the urine pregnancy test result is not confirmatory, a serum pregnancy test is required. A female not of childbearing potential is defined as being postmenopausal for at least 1 year, or surgically sterilized, or having undergone a hysterectomy.\n\nExclusion Criteria:\n\n* 1\\. Diagnosis of malignancies other than liver cancer within 5 years prior to the first dose.\n\n  2\\. Intrahepatic or extrahepatic cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, fibrolamellar HCC, ampullary tumors, or other biliary tract malignancies.\n\n  3\\. Prior treatment with any JAK inhibitor.\n\n  4\\. Patients with pleural effusion, ascites, or pericardial effusion requiring drainage, who are clinically assessed as unable to tolerate the study treatment.\n\n  5\\. History of esophageal or gastric variceal bleeding due to portal hypertension within 6 months prior to the first dose; or current imaging (contrast-enhanced CT or MRI) confirming significant esophageal or gastric varices.\n\n  6\\. History of severe bleeding tendency or coagulopathy; clinically significant hemorrhagic symptoms within 1 month prior to the first dose (including but not limited to gastrointestinal bleeding, hemoptysis, epistaxis)\n\n  7\\. History of myocarditis, cardiomyopathy, or malignant arrhythmia\n\n  8\\. History of immunodeficiency; positive HIV antibody test; current long-term use of systemic corticosteroids or other immunosuppressants; active autoimmune disease requiring systemic treatment within the past two years.\n\n  9\\. Known active tuberculosis (TB).\n\n  10\\. Known active syphilis infection.\n\n  11\\. Administration of a live or live-attenuated vaccine within 30 days prior to the first dose.\n\n  12\\. History of mental illness, drug abuse, alcoholism, or substance abuse.\n\n  13\\. Pregnant or lactating women.","ALL","18 Years","75 Years",{"count":19,"type":20},65,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Background： Hepatocellular carcinoma (HCC) stands as a formidable global health challenge. It ranks as the sixth most common malignant solid tumor worldwide and the third leading cause of cancer-related mortality. The disease is characterized by its insidious onset, rapid progression, and high recurrence rates, contributing to a dismal 5-year survival rate of approximately 18%. A critical factor in this poor prognosis is that nearly 57% of patients are diagnosed at an advanced stage, where curative surgical resection is no longer feasible. For these patients with unresectable advanced HCC (uHCC), effective systemic therapies are paramount to extend survival and improve quality of life.\n\nThe advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting the PD-1\u002FPD-L1 axis, has revolutionized the treatment landscape for numerous advanced cancers, including uHCC. These agents work by blocking the inhibitory signals that tumor cells exploit to evade immune surveillance, thereby reactivating cytotoxic T cells to attack the cancer.\n\nHowever, the clinical benefit of ICI-based therapies is not universal. A substantial proportion of patients-estimated between 15% to 40%-derive limited or no benefit. Primary resistance is defined as a lack of initial response, while acquired resistance refers to disease progression after an initial period of clinical benefit. There is no established, evidence-based standard of therapy for uHCC patients who progress following first-line ICI combination therapy, highlighting an urgent need for novel therapeutic approaches.\n\nThe mechanisms underlying acquired resistance to ICIs are multifaceted and intricately linked to dynamic remodeling of the tumor immune microenvironment (TME). Several key pathways contribute:\n\n1. Loss of Tumor Immunogenicity: Immune editing during treatment can select for tumor cell clones with low neoantigen expression, making them less visible to the immune system.\n2. Immune Suppressive Cell Infiltration: The TME in resistant tumors often exhibits an accumulation of immunosuppressive cell populations, including regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs). These cells create a profoundly inhibitory milieu that dampens anti-tumor T cell function.\n3. T Cell Exhaustion: Persistent antigen exposure leads to a state of CD8⁺ T cell exhaustion, rendering them dysfunctional.\n\nThese interconnected mechanisms collectively foster an immunosuppressive TME that allows tumors to evade ongoing immune attack, underscoring the need for combination strategies that can reshape the TME and re-sensitize tumors to immunotherapy.\n\nThe JAK-STAT pathway serves as a critical signaling hub for numerous cytokines and growth factors, playing a pivotal dual role in immunity and inflammation. In the context of HCC and ICI resistance, its activation is particularly relevant:\n\n1. Pathway Activation in HCC: The JAK\u002FSTAT pathway is ubiquitously activated in both primary and recurrent HCC tumors and contributes to the proliferation and survival of tumor-initiating cells.\n2. Driver of an Immunosuppressive TME: Hyperactivation of this pathway, often via cytokines like IL-6, promotes the recruitment and activation of immunosuppressive MDSCs and M2-polarized TAMs. It also contributes to T cell exhaustion.\n3. Preclinical and Clinical Proof-of-Concept: In preclinical models, JAK\u002FSTAT inhibition has been shown to reduce MDSC infiltration and restore T cell function. Most compellingly, recent clinical studies in other cancer types published in high-impact journals like Science (2024) have demonstrated that adding a JAK inhibitor to PD-1 blockade can re-sensitize tumors and yield significant clinical responses in patients who had developed resistance to immunotherapy alone\n\nPurpose:\n\nThis single-arm, exploratory clinical study aims to evaluate the efficacy and safety of Ivarmacitinib (a selective JAK1 inhibitor) combined with Camrelizumab (anti-PD-1) and Apatinib (anti-VEGFR2) in patients with advanced unresectable HCC who have progressed after first-line ICI-based combination therapy.\n\nMethods:\n\nThis study plans to enroll 65 patients with advanced unresectable hepatocellular carcinoma (unresectable BCLC stage B or stage C) who have been clinically or pathologically diagnosed, have previously received at least 4 cycles of guideline-recommended first-line targeted therapy combined with PD-1\u002FPD-L1 immunotherapy, achieved a partial response, but subsequently experienced disease progression confirmed by RECIST 1.1 criteria after at least 4 cycles (indicating acquired resistance).\n\nAll enrolled patients will receive triple therapy consisting of Ivarmacitinib + Apatinib + Camrelizumab. Treatment will continue until disease progression, unacceptable toxicity, or for up to 2 years.",[26,27,28,29],"Hepatocellular Carcinomas","Resistance to Immunotherapy","Immunomodulation","Drug Repurposing","NOT_YET_RECRUITING","2025-12-24",{"date":33,"type":34},"2026-01-07","ACTUAL",{"date":36,"type":20},"2026-01-01",{"date":38,"type":20},"2029-01-01",{"name":40,"class":41},"First Affiliated Hospital of Chongqing Medical University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100594657","phase-2-sintilimab-plus-anlotinib-as-second-or-further-line-therapy-for-es-sclc-who-have-progressed-after-anti-pd-1l1-therapy-100594657","NCT07022301","Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1\u002FL1 Therapy","A Phase II Study Evaluating the Safety and Efficacy of Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti- PD- 1\u002FL1 Therapy","Inclusion Criteria:\n\n* 1\\. At the time of signing the informed consent form, both men and women must be at least 18 years old.\n* 2\\. Widespread recurrent small cell lung cancer diagnosed by histology or cytology and progressing after 3 months of standard immunization.\n* 3\\. According to RECIST 1.1 criteria, patients must have at least one measurable lesion (lesions that have undergone radiotherapy must show clear progression in order to be considered measurable lesions).\n* 4\\. ECOG PS score: 0-1 points.\n* 5\\. Expected survival period ≥ 3 months.\n* 6\\. Important organ functions must meet the following standards:\n\n  1\\) Blood routine examination: (No blood transfusion or use of cytokine drugs such as G-CSF for corrective treatment within 2 weeks before screening)\n  1. Hemoglobin (HB) ≥ 90 g\u002FL;\n  2. Absolute neutrophil count (ANC) ≥ 1.5 × 10\\*9\u002FL;\n  3. Platelet count (PLT) ≥ 90 × 10\\*9\u002FL;\n  4. White blood cell count (WBC) ≥ 3.0 × 109\u002FL and\\\u003C15 × 10\\*9\u002FL; 2) Other tests: (did not receive human serum albumin injection within 14 days before screening)\n  5. AST and ALT ≤ 3 x ULN;\n  6. ALP ≤ 2.5 x ULN (≤ 5 x ULN if there is bone metastasis);\n  7. TBiL≤1x ULN；\n  8. ALB≥30g\u002FL；\n  9. Cr ≤ 1.5 x ULN, while creatinine clearance rate (CrCL) ≥ 60mL\u002Fmin (Cockcroft Gault formula);\n  10. TSH ≤ 1 x ULN (if abnormal, FT3 and FT4 levels should be examined simultaneously. If FT3 and FT4 levels are normal, they can be included in the group)\n  11. APTT ≤ 1.5 x ULN, while INR or PT ≤ 1.5 x ULN (not receiving anticoagulant therapy).\n  12. Male QTc\\\u003C450 ms, female QTc\\\u003C470 ms, LVEF ≥ 50%\n* 7\\. Non surgical sterilization or female patients of childbearing age must undergo a serum pregnancy test within 3 days before the first medication, and the result must be negative; And it must be non lactating. Female patients of childbearing age or male patients with partners of childbearing age must agree to use efficient contraception methods during the study period and within 6 months after the last administration of the study drug.\n* 8\\. The patient voluntarily joined this clinical study and signed an informed consent form, with good compliance and the ability to cooperate with follow-up.\n\nExclusion Criteria:\n\n* 1\\. Imaging shows that the tumor has invaded large blood vessels or has unclear boundaries with blood vessels.\n* 2\\. Imaging shows the presence of obvious pulmonary hollow or necrotic tumors.\n* 3\\. Symptomatic central nervous system metastases (such as brain metastases or meningeal metastases).\n* 4\\. Patients with conditions such as malignant meningitis and spinal cord compression.\n* 5\\. Persons who have suffered from other malignant tumors in the past or at the same time, unless they are skin basal cell carcinoma, superficial bladder cancer, skin squamous cell carcinoma, cervical carcinoma in situ or other carcinoma in situ that have achieved complete remission at least 5 years before screening and do not need or are not expected to need other treatment during the study period.\n* 6\\. Those who have had or currently have objective evidence of idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, tissue pneumonitis (such as bronchitis, occlusive vasculitis), drug-induced pneumonia, or screening period CT showing active pneumonia or lung function examination confirming severe impairment of lung function.\n* 7\\. Individuals with any active, known or suspected autoimmune diseases (including but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, enteritis, multiple sclerosis, vasculitis, glomerulonephritis, uveitis, pituitary inflammation, hyperthyroidism, etc.). Type I diabetes patients who are allowed to receive stabilizing dose insulin treatment, hypothyroidism patients who only need hormone replacement treatment, and skin diseases (such as eczema, vitiligo, or psoriasis) that do not require systemic treatment and have no acute deterioration within 1 year before the screening period.\n* 8\\. Patients suspected of having active pulmonary tuberculosis should undergo chest X-ray, sputum examination, and exclusion based on clinical symptoms and signs. Individuals with a history of active pulmonary tuberculosis infection within the previous year should be excluded, even if they have been treated; Subjects with a history of active pulmonary tuberculosis infection more than one year ago should also be excluded unless it is proven that the previous course and type of anti tuberculosis treatment used were appropriate.\n* 9\\. Clinical symptoms or diseases of the heart that have not been well controlled, such as: (1) NYHA grade 2 or above heart failure, (2) unstable angina, (3) myocardial infarction within 1 year, and (4) clinically significant supraventricular or ventricular arrhythmias that require treatment or intervention.\n* 10\\. Patients with hypertension who cannot achieve good control with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg).\n* 11\\. Urine routine showed urinary protein ≥++, and 24-hour urinary protein quantification was confirmed to be\\>1.0 g through quantitative detection of urinary protein.\n* 12\\. For individuals with a tendency towards thrombosis or undergoing thrombolytic\u002Fanticoagulant therapy, prophylactic use of low-dose aspirin (≤ 100mg\u002Fd) and low molecular weight heparin (≤ 40mg\u002Fd) is allowed.\n* 13\\. Those who have received\\>30 Gy of chest radiation therapy within the first 6 months of randomization, and have undergone major surgical treatment within the first 4 weeks of randomization, but have not recovered from the toxicity and\u002For complications of previous intervention measures to NCI-CTC AE ≤ 1 degree (except for hair loss and indicators clearly defined in the inclusion criteria).\n* 14\\. Within the first 6 months of randomization, there have been arterial\u002Fvenous thrombotic events, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism.\n* 15\\. Individuals with a daily cough\u002Fhemoptysis volume greater than 2.5mL within the first month of randomization. Individuals with a history of hereditary or acquired bleeding or coagulation dysfunction. Within the first 3 months of randomization, there have been significant clinical bleeding symptoms or clear bleeding tendencies, such as gastrointestinal bleeding, hemorrhagic gastric ulcers, etc.\n* 16\\. Participants who have experienced severe infections within the previous month prior to randomization, including but not limited to infection complications requiring hospitalization, bacteremia, severe pneumonia, etc; Subjects with any active infection, or experiencing unexplained fever\\>38.5 ℃ during screening or before the first dose.\n* 17\\. Patients who have received anti-tumor vaccines or other immunomodulatory drugs (such as interleukin-2, thymosin, shiitake polysaccharides, etc.) within the previous month of randomization, or patients who will receive attenuated live vaccines.\n* 18\\. Subjects who have received systemic therapy with corticosteroids (\\>10 mg\u002Fday of prednisone or other equivalent hormones) or other immunosuppressive agents within the previous month prior to randomization. In the absence of active autoimmune diseases, inhalation or topical use of corticosteroids, as well as adrenal hormone replacement therapy with a dose ≤ 10 mg\u002Fday of prednisone efficacy dose, are allowed.\n* 19\\. Known to have a positive history of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). It is known that there is active hepatitis or co infection with hepatitis B and hepatitis C. (hepatitis B reference: HBsAg is positive, and the HBV DNA detection value exceeds the upper limit of normal value; Hepatitis C reference: HCV antibody positive and HCV virus titer detection value exceeding the upper limit of normal.\n* 20\\. are known to have experienced allergic reactions to other monoclonal antibodies or any component of anlotinib.\n* 21\\. Those who are currently participating in other clinical studies or have been randomized for less than 4 weeks (or 5 half lives of the study drug) since the end of the previous clinical study (last dose);\n* 22\\. According to the researchers' assessment, there are other factors that may affect the research results or lead to the forced termination of this study, such as alcohol abuse, drug use, drug abuse, other serious illnesses (including mental illnesses) that require concurrent treatment, serious laboratory test abnormalities, and family or social factors that may affect medication safety.",{"count":51,"type":20},25,[23],"The phase II study enrolled ES-SCLC patients who had disease progression after anti-PD-1\u002FL1 therapy. Participants received intravenous sintilimab 200 mg on day one and oral daily anlotinib 8-12 mg on days 1-14 once every three weeks per cycle. The primary endpoint was objective response rate (ORR). The secondary endpoints included overall survival (OS), progression-free survival (PFS) , disease control rate (DCR) and safety.",[55,27],"Small Cell Lung Cancer Extensive Stage","2025-06-12",{"date":58,"type":34},"2025-06-15",{"date":60,"type":20},"2025-07",{"date":62,"type":20},"2029-05",{"name":64,"class":41},"First Affiliated Hospital of Wannan Medical College",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":85,"locationsCount":4},"100594036","phase-2-pd-1-combined-with-bevacizumab-and-pcsk-9-inhibitor-in-patients-with-advanced-nsclc-who-have-progressed-after-anti--pd--1l1-therapy-100594036","NCT07014215","PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1\u002FL1 Therapy","A Phase II Study Evaluating the Safety and Efficacy of Sintilimab Plus Bevacizumab and Tafolecimab in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1\u002FL1 Therapy","Inclusion Criteria:\n\n* 1\\. Sign written informed consent before implementing any experimental procedures\n* 2\\. Age ≥ 18 years old and ≤ 80 years old\n* 3\\. Histological or cytological confirmation of locally advanced (IIIB-IIIC), metastatic or recurrent (stage IV) NSCLC (International Association for the Study of Lung Cancer and Joint Committee on Cancer Classification 9th edition TNM lung cancer staging)\n* 4\\. Failure after previous treatment with PD - (L) 1 inhibitors (alone or in combination with another systemic therapy) (CR, PR, SD\\>6 months)\n* 5\\. Previously not receiving anti angiogenic drug treatment\n* 6\\. Confirmed by histological specimens that there are no EGFR gene sensitive mutations, ALK gene fusion mutations, ROS1 gene mutations, or RET gene mutations\n* 7\\. According to the criteria for evaluating the efficacy of solid tumors (RECIST v1.1 version), there should be at least one measurable lesion on imaging. If the lesion located within the previous radiation field is confirmed to have progressed, it can be considered a measurable lesion\n* 8\\. Subjects with brain metastases who are asymptomatic or have stable symptoms after local treatment are allowed to be enrolled, as long as they meet the following conditions:\n\n  1. Measurable lesions outside the central nervous system\n  2. No central nervous system symptoms or no worsening of symptoms within at least 2 weeks\n  3. No need for glucocorticoid treatment, or discontinuation of glucocorticoid treatment within 7 days prior to the first dose, or stable and reduced glucocorticoid dosage to below 10mg\u002Fday of prednisone (or equivalent dose) within 7 days prior to the first dose\n* 9\\. Subjects are allowed to receive palliative radiation therapy (including cranial radiation therapy for symptomatic brain metastases), provided that the radiation therapy is completed at least one week before enrollment and the radiation related toxicity has recovered to less than or equal to degree 1 (CTCAE 5.0, except for hair loss)\n* 10\\. ECOG rating 0-1 points\n* 11\\. Expected survival time\\>3 months\n* 12\\. Adequate organ function, subjects must meet the following laboratory indicators:\n\n  1. In the past 14 days without using granulocyte colony-stimulating factor, the absolute neutrophil count (ANC) is ≥ 1.5x10\\*9\u002FL\n  2. Platelets ≥ 100 × 10\\*9\u002FL without blood transfusion in the past 14 days\n  3. Hemoglobin\\>9g\u002FdL without blood transfusion or use of erythropoietin in the past 14 days\n  4. Total bilirubin ≤ 1.5 x upper limit of normal (ULN)\n  5. Aspartate transaminase (AST) and alanine transaminase (ALT) levels should be ≤ 2.5 × ULN (subjects with liver metastases are allowed to have ALT or AST levels ≤ 5 × ULN)\n  6. Blood creatinine ≤ 1.5 × ULN and creatinine clearance rate (calculated using Cockcroft Gault formula) ≥ 60 ml\u002Fmin\n  7. Good coagulation function, defined as International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 times ULN\n  8. Normal thyroid function is defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH exceeds the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled\n  9. The myocardial enzyme spectrum is within the normal range (simple laboratory abnormalities that are deemed clinically insignificant by the researchers are also allowed to be included)\n* 13\\. For female subjects of childbearing age, a urine or serum pregnancy test with negative results should be conducted within 3 days prior to the first administration of the study drug (Day 1 of the first cycle). If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Non childbearing women are defined as those who have been postmenopausal for at least one year or have undergone surgical sterilization or hysterectomy\n* 14\\. If there is a risk of conception, all subjects (regardless of gender) must use contraceptive measures with an annual failure rate of less than 1% throughout the entire treatment period until 120 days (or 180 days) after the last administration of the study drug\n\nExclusion Criteria:\n\n* 1\\. Pathological diagnosis of small cell lung cancer (SCLC), including lung cancer mixed with SCLC and NSCLC\n* 2\\. The patient has received first-line or more PD - (L) 1 inhibitor monotherapy or combination chemotherapy treatment\n* 3\\. Received the following treatments:\n\n  1. Received systemic anti-tumor therapy within 3 weeks prior to treatment, such as chemotherapy, targeted therapy, immunotherapy (including herbal therapy with anti-tumor indications), etc\n  2. Received any investigational drug treatment within 4 weeks prior to treatment\n  3. Received high doses of immunosuppressive drugs (systemic corticosteroids exceeding 10mg\u002Fday, prednisone or its equivalent) within 4 weeks prior to treatment\n  4. Received attenuated live vaccine within 4 weeks prior to treatment (or planned to receive attenuated live vaccine during the study period)\n  5. Has undergone major surgery (such as open cavity, thoracotomy, or Kaifu surgery) within 4 weeks before treatment, or has unhealed surgical wounds, ulcers, or fractures\n* 4\\. There is clinically uncontrollable pleural\u002Fperitoneal effusion (subjects who do not require drainage or have no significant increase in effusion after stopping drainage for 3 days can be enrolled)\n* 5\\. Subjects who have received chest radiation therapy greater than 30 Gy within the 6 months prior to treatment or palliative radiation therapy with a dose of 30 Gy or less within the 7 days prior to treatment (palliative radiation therapy for bone lesions or intracranial lesions is allowed)\n* 6\\. Within 2 years prior to the first administration, there has been an active autoimmune disease requiring systemic treatment (such as the use of disease relieving drugs, corticosteroids, or immunosuppressants). Alternative therapies (such as thyroid hormone, insulin, or physiological glucocorticoids used for adrenal or pituitary insufficiency) are not considered systemic treatments\n* 7\\. Known allogeneic organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation\n* 8\\. Individuals known to be allergic to the active ingredients or excipients of the study drug\n* 9\\. Before starting treatment, if there has been no sufficient recovery from toxicity and\u002For complications caused by any intervention measures (i.e. ≤ grade 1 or baseline, excluding fatigue or hair loss)\n* 10\\. Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1\u002F2 antibody positive)\n* 11\\. Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number detected is greater than the upper limit of normal value in the laboratory of the research center) Note: Those who meet the following criteria can also be included in the group:\n\n  1. Before the first administration, the HBV viral load was less than 1000 copies\u002Fml (200 IU\u002Fml), and subjects should receive anti HBV treatment throughout the entire study drug treatment period to avoid viral reactivation\n  2. For subjects with anti HBc (+), HBsAg (-), anti HBs (-), and HBV viral load (-), prophylactic anti HBV treatment is not necessary, but close monitoring of viral reactivation is necessary\n* 12\\. Active HCV infected subjects (HCV antibody positive and HCV-RNA level above the detection limit)\n* 13\\. Administer a live vaccine within 30 days prior to the first dose (Day 1 of the first cycle) Note: It is allowed to receive inactivated vaccine for seasonal influenza within 30 days before the first administration; But it is not allowed to receive attenuated live influenza vaccine for intranasal use\n* 14\\. Pregnant or lactating women\n* 15\\. There are any serious or uncontrollable systemic diseases, such as:\n\n  1. Resting electrocardiogram shows significant and difficult to control abnormalities in rhythm, conduction, or morphology, such as complete left bundle branch block, grade II or higher heart block, ventricular arrhythmia, or atrial fibrillation\n  2. Unstable angina pectoris, congestive heart failure, chronic heart failure classified as NYHA ≥ 2\n  3. Myocardial infarction occurred within 6 months prior to enrollment\n  4. Poor blood pressure control (systolic blood pressure\\>140 mmHg, diastolic blood pressure\\>90 mmHg)\n  5. A history of non infectious pneumonia requiring corticosteroid treatment within the year prior to the first administration, or current clinical active interstitial lung disease\n  6. Active pulmonary tuberculosis\n  7. There are active or uncontrolled infections that require systemic treatment\n  8. Presence of clinically active diverticulitis, abdominal abscess, and gastrointestinal obstruction\n  9. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis\n  10. Poor control of diabetes (FBG\\>10mmol\u002FL)\n  11. Urine routine shows urinary protein ≥++and confirms 24-hour urinary protein quantification\\>1.0 g\n  12. Subjects with mental disorders who are unable to cooperate with treatment\n* 16\\. Medical history or disease evidence that may interfere with the trial results, hinder the full participation of the subjects in the study, abnormal treatment or laboratory test values, or other situations that the researchers believe are not suitable for inclusion. The researchers believe that there are other potential risks that are not suitable for participation in this study","80 Years",{"count":74,"type":20},52,[23],"This study evaluated the sintilimab combination of bevacizumab and tafolecimab in NSCLC patients who have previously been treated with anti- PD- 1\u002Fligand (L)1 and acquired resistance. The patients were assigned to receive sintilimab(200mg Q3W) in combination with bevacizumab(7.5mg\u002Fkg Q3W) and tafolecimab(600 mg Q6W). The primary endpoints of the study were progression- free survival (PFS) assessed by RECISTv1.1 , while secondary endpoints included objective response rate (ORR), and overall survival (OS) and safety.",[78,27],"NSCLC (Advanced Non-small Cell Lung Cancer)","2025-06-09",{"date":81,"type":34},"2025-06-10",{"date":83,"type":20},"2025-06",{"date":62,"type":20},{"name":86,"class":41},"Anhui Provincial Cancer Hospital"]